Effect of long-term antihypertensive treatment on white-coat hypertension

Hypertension

Volumn 64, Issue 6, 2014, Pages 1388-1398

  Mancia, Giuseppe ^a,b   Facchetti, Rita ^b   Parati, Gianfranco ^a,b   Zanchetti, Alberto ^a,c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Antihypertensive agents; Hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ATENOLOL; DIHYDROPYRIDINE DERIVATIVE; LACIDIPINE; MUTAGENIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; WHITE COAT HYPERTENSION; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

AGED; ATENOLOL; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTAGENS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WHITE COAT HYPERTENSION;

EID: 84922480151     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04278     Document Type: Article

References (58)

1. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens. 2011;24:52-58.
2. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
3. Eguchi K, Hoshide S, Ishikawa J, Ishikawa S, Pickering TG, Gerin W, Ogedegbe G, Schwartz JE, Shimada K, Kario K. Cardiovascular prognosis of sustained and white-coat hypertension in patients with type 2 diabetes mellitus. Blood Press Monit. 2008;13:15-20.
4. Dolan E, Stanton A, Atkins N, Den Hond E, Thijs L, McCormack P, Staessen J, O'Brien E. Determinants of white-coat hypertension. Blood Press Monit. 2004;9:307-309.
5. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Sympathetic neural mechanisms in white-coat hypertension. J Am Coll Cardiol. 2002;40:126-132.
6. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846-853.
7. Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, Grassi G. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168-174.
8. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Grassi G, Sega R. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens. 2009;27:1672-1678.
9. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, Grassi G, Sega R. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226-232.
10. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in whitecoat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25:2193-2198.
11. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T, Kario K. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203-208.
12. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with whitecoat and sustained hypertension. J Am Coll Cardiol. 2001;38:238-245.
13. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation. 1998;98:1892-1897.
14. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Blood pressure monitoring. Task force V: white-coat hypertension. Blood Press Monit. 1999;4:333-341.
15. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712-718.
16. De La Sierra A, Segura J, Banegas JR, Gorostidi M, De La Cruz JJ, Armario P, Oliveras A, Ruilope M. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-992.
17. Fitscha P, Meisner W. Antihypertensive effect of isradipine on ambulatory and casual blood pressure. Am J Hypertens. 1993;6(3 Pt 2):67S-69S.
18. Weber MA, Cheung DG, Graettinger WF, Lipson JL. Characterization of antihypertensive therapy by whole-day blood pressure monitoring. JAMA. 1988;259:3281-3285.
19. Høegholm A, Wiinberg N, Kristensen KS. The effect of antihypertensive treatment with dihydropyridine calcium antagonists on white-coat hypertension. Blood Press Monit. 1996;1:375-380.
20. Kruszewski P, Bieniaszewski L, Neubauer J, Krupa-Wojciechowska B. Headache in patients with mild to moderate hypertension is generally not associated with simultaneous blood pressure elevation. J Hypertens. 2000;18:437-444.
21. Herpin D, Vaisse B, Pitiot M, De Gaudemaris R, Mallion JM, Poggi L, Demange J. Comparison of angiotensin-converting enzyme inhibitors and calcium antagonists in the treatment of mild to moderate systemic hypertension, according to baseline ambulatory blood pressure level. Am J Cardiol. 1992;69:923-926.
22. Kristensen KS, Høegholm A. White-coat hypertension. Lancet. 1996;348:1444; author reply 1445-1444; author reply 1446.
23. Yamagishi T. Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension. Hypertens Res. 2006;29:339-344.
24. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation. 2000;102:1139-1144.
25. Bulpitt CJ, Beckett N, Peters R, Staessen JA, Wang JG, Comsa M, Fagard RH, Dumitrascu D, Gergova V, Antikainen RL, Cheek E, Rajkumar C. Does white coat hypertension require treatment over age 80? Results of the hypertension in the very elderly trial ambulatory blood pressure side project. Hypertension. 2013;61:89-94.
26. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-140.
27. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group. Am J Hypertens. 1994;7(9 Pt 1):848-852.
28. Franklin SS, Thijs L, Hansen TW, et al; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension. 2012;59:564-571.
29. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P; European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422-2427.
30. Mancia G, Zanchetti A. White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? J Hypertens. 1996;14:1049-1052.
31. Mancia G. Short- and long-term blood pressure variability: present and future. Hypertension. 2012;60:512-517.
32. O'Brien E, Parati G, Stergiou G, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731-1768.
33. Casadei R, Parati G, Pomidossi G, Groppelli A, Trazzi S, Di Rienzo M, Mancia G. 24-hour blood pressure monitoring: evaluation of Spacelabs 5300 monitor by comparison with intra-arterial blood pressure recording in ambulant subjects. J Hypertens. 1988;6:797-803.
34. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
35. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30:1241-1251.
36. Mancia G, Parati G, Bilo G, et al. Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension. 2012;60:1400-1406.
37. Mancia G, Parati G, Bilo G, Choi J, Kilama MO, Ruilope LM; TALENT Investigators. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. J Hypertens. 2011;29:600-609.
38. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Sacchi N, Guerrieri M, Comparato E, Porcellati C. Identification of subjects with white-coat hypertension and persistently normal ambulatory blood pressure. Blood Press Monit. 1996;1:217-222.
39. Verdecchia P. The clinical value of circadian variations of blood pressure. Blood Press Monit. 1997;2:297-299.
40. Parati G, Ulian L, Santucciu C, Omboni S, Mancia G. Difference between clinic and daytime blood pressure is not a measure of the white coat effect. Hypertension. 1998;31:1185-1189.
41. Sega R, Cesana G, Milesi C, Grassi G, Zanchetti A, Mancia G. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension. 1997;30(1 Pt 1):1-6.
42. Salice P, Ardissino G, Barbier P, Bacà L, Vecchi DL, Ghiglia S, Colli AM, Galli MA, Marra G, Testa S, Edefonti A, Magrini F, Zanchetti A. Differences between office and ambulatory blood pressures in children and adolescents attending a hospital hypertension clinic. J Hypertens. 2013;31:2165-2175.
43. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
44. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
45. Report by the Management Committee. The Australian therapeutic trial in mild hypertension. Lancet. 1980;1:1261-1267.
46. Medical Research Council Working Party. MRC Trial of treatment of mild hypertension: principal results. Br Med J. 1985;291:97-104.
47. Zhang Y, Zhang X, Liu L, Zanchetti A; FEVER Study Group. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of fndings from the randomized FEVER trial. Eur Heart J. 2011;32:1500-1508.
48. Hypertension Detection and Follow-up Program Cooperative Group. Five-year fndings on the hypertension detection and follow-up program III. Reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:633-638.
49. Verdecchia P, Palatini P, Schillaci G, Mormino P, Porcellati C, Pessina A. Independent predictors of isolated clinic ("white-coat") hypertension. J. Hypertens. 2001;19:1755-1763.
50. Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension. 1997;29(1 Pt 1):22-29.
51. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-1783.
52. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation. 2012;126:569-578.
53. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Giannattasio C, Grassi G, Sega R. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens. 2008;26:1602-1611.
54. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, Valagussa F, Bombelli M, Giannattasio C, Zanchetti A, Mancia G. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001;104:1385-1392.
55. Mancia G, Omboni S, Parati G, Clement DL, Haley WE, Rahman SN, Hoogma RP. Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. J Hypertens. 2001;19:1755-1763.
56. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Grassi G, Sega R. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension. 2007;49:1265-1270.
57. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension. 2000;36:901-906.
58. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation. 2000;102:1536-1541.